Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.

@article{Aaboe2010TwelveWT,
  title={Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.},
  author={Kasper Aaboe and Filip Krag Knop and Tina Vilsb\oll and Carolyn F Deacon and Jens Juul Holst and Sten Madsbad and Thure Krarup},
  journal={Diabetes, obesity & metabolism},
  year={2010},
  volume={12 4},
  pages={323-33}
}
AIM To examine the effects of 12 weeks of treatment with the DPP-4 inhibitor, sitagliptin, on gastrointestinal hormone responses to a standardized mixed meal and beta cell secretory capacity, measured as glucose and non-glucose induced insulin secretion during a hyperglycaemic clamp, in patients with type 2 diabetes. METHOD A double-blinded, placebo-controlled study over 12 weeks in which 24 patients with T2DM were randomized to receive either sitagliptin (Januvia) 100 mg qd or placebo as an… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 43 extracted citations

Similar Papers

Loading similar papers…